U.S. Software Stock News

NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals (CPRX)?

In recent days, Catalyst Pharmaceuticals has been highlighted for strong earnings and revenue growth, solid profitability, and a debt-free balance sheet, earning it a spot on an “Affordable Growth” screen. At the same time, upbeat analyst views and collaborations with BioMarin Pharmaceutical and Endo Ventures have reinforced Catalyst’s rare-disease focus as a key differentiator in the biotechnology space. We’ll now examine how Catalyst’s combination of robust financial health and...
NYSE:LAZ
NYSE:LAZCapital Markets

Lazard (LAZ) Margin Compression To 7.6% Tests Bullish Earnings Growth Narratives

Lazard (LAZ) has capped FY 2025 with fourth quarter revenue of US$906.7 million, basic EPS of US$0.50 and net income excluding extra items of US$49.9 million, setting a clear marker for how the year wrapped up. The firm has seen quarterly revenue move from US$811.4 million in Q4 2024 to US$906.7 million in Q4 2025, while Q4 EPS shifted from US$0.89 to US$0.50 over the same stretch, giving investors a mixed read on top line scale and per share profitability as they weigh what softer margins...
NYSE:NNN
NYSE:NNNRetail REITs

NNN REIT Extends Dividend Streak As Valuation Screens Undervalued

NNN REIT affirmed its regular quarterly dividend, extending its 36-year streak of consecutive annual dividend growth. The decision underscores management’s focus on income stability and long term capital returns for shareholders. Management continues to emphasize rent growth and acquisitions as key supports for the dividend policy. NNN REIT, traded as NYSE:NNN, reconfirmed its dividend at a time when income focused investors are paying close attention to payout consistency. The stock last...
NYSE:MPLX
NYSE:MPLXOil and Gas

Is MPLX (MPLX) Still Attractively Priced After Its Recent Strong Share Price Run?

If you are wondering whether MPLX is still reasonably priced after its strong run, this article will help you make sense of where the current share price sits against different views of value. With the stock at US$56.24 and returns of 1.2% over 7 days, 4.8% over 30 days, 4.4% year to date and 13.9% over 1 year, many investors are asking whether the recent performance reflects growth potential or a shift in perceived risk. Over the past few months, MPLX has attracted attention as investors...
NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Gold Royalty (GROY) Valuation After Borborema Royalty Deal And Record Preliminary Revenue

Gold Royalty (GROY) has been in focus after reporting preliminary revenue of US$4,501,000 for the quarter and US$15,610,000 for 2025, alongside acquiring a net smelter royalty on Brazil’s Borborema gold mine. See our latest analysis for Gold Royalty. At a share price of US$4.65, Gold Royalty has seen a 26.02% 90 day share price return and a very large 263.28% 1 year total shareholder return. This suggests recent momentum that contrasts with the 1 day and 7 day pullback, as the market weighs...